Prebiotic Xylooligosaccharides Alleviate Metabolic Liver Disease via Gut Microbiota Modulation
- Research published in Nature has identified that high-dose xylooligosaccharides (XOS) can significantly ameliorate metabolic dysfunction-associated steatotic liver disease (MASLD) by modulating gut microbiota and microbial metabolites.
- XOS are prebiotics derived from algae and lignocellulosic biomass.
- The study utilized male C57BL/6 mice divided into four groups: a low-fat diet (LFD) group, a high-fat diet (HFD) group, an HFD group supplemented with low-dose XOS (0.38...
Research published in Nature has identified that high-dose xylooligosaccharides (XOS) can significantly ameliorate metabolic dysfunction-associated steatotic liver disease (MASLD) by modulating gut microbiota and microbial metabolites. The study suggests that dose optimization is critical for the efficacy of XOS-based interventions in treating this liver condition.
XOS are prebiotics derived from algae and lignocellulosic biomass. They consist of β-D-xylopyranose units linked by β-glycosidic bonds, making them resistant to mammalian digestion but fermentable by beneficial gut bacteria.
Clinical Findings and Dose Response
The study utilized male C57BL/6 mice divided into four groups: a low-fat diet (LFD) group, a high-fat diet (HFD) group, an HFD group supplemented with low-dose XOS (0.38 g/kg), and an HFD group supplemented with high-dose XOS (1.0 g/kg) over a 16-week period.
Results indicated a clear dose-dependent response. High-dose XOS significantly reduced serum triglycerides (TG) and Alanine aminotransferase (ALT) levels. The high-dose intervention alleviated hepatic steatosis and improved the villus height–to–crypt depth ratio in the ileum.
In contrast, the low-dose XOS supplementation did not produce these significant reductions in ALT and TG levels or the same level of improvement in hepatic steatosis.
Impact on Gut Microbiota and Metabolites
The administration of high-dose XOS altered the composition of the gut microbiota in HFD-fed mice. Specifically, it attenuated the HFD-induced enrichment of Lachnospiraceae and Ruminococcaceae.
Simultaneously, high-dose XOS restored the abundance of the following bacterial families:
- Bacteroidaceae
- Bifidobacteriaceae
- Bacillaceae
Metabolomic analysis further revealed that high-dose XOS rebalanced the arachidonic-acid and tryptophan–indole pathways. This resulted in an increase of omega-3 polyunsaturated fatty acids and hepatoprotective indole derivatives, while reducing kynurenine derivatives and pro-inflammatory eicosanoids.
These changes effectively reconstructed the gut microbiota-metabolite network toward a hepatoprotective and anti-inflammatory state.
Broader Health and Market Implications
Beyond MASLD, XOS are recognized as promising prebiotics with the capacity to selectively modulate gut microbiota to support digestive and metabolic health. They have a bifidogenic effect, which stimulates the production of short-chain fatty acids (SCFAs) and suppresses the proliferation of pathogens.
Additional evidence suggests XOS may offer benefits in other areas of metabolic and systemic health, including:
- Improving lipid profiles and reducing inflammation.
- Improving markers for type 2 diabetes and obesity.
- Enhancing oxidative stress resistance and demonstrating anticancer properties by reducing tumor cell proliferation.
- Restoring general gut homeostasis.
The ability of XOS to influence immune function and metabolic parameters makes them a significant area of interest for the development of prebiotic-based interventions for various metabolic disorders.